<?xml version="1.0" encoding="utf-8"?>
<doi_batch xmlns="http://www.crossref.org/schema/4.3.6" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:jats="http://www.ncbi.nlm.nih.gov/JATS1" xmlns:ai="http://www.crossref.org/AccessIndicators.xsd" xmlns:fr="http://www.crossref.org/fundref.xsd" version="4.3.6" xsi:schemaLocation="http://www.crossref.org/schema/4.3.6 https://www.crossref.org/schemas/crossref4.3.6.xsd">
  <head>
    <doi_batch_id>_1705327577</doi_batch_id>
    <timestamp>20240115140617000</timestamp>
    <depositor>
      <depositor_name>Editor</depositor_name>
      <email_address>editor.jddt@gmail.com</email_address>
    </depositor>
    <registrant>Universal Journal of Pharmaceutical Research</registrant>
  </head>
  <body>
    <journal>
      <journal_metadata>
        <full_title>Universal Journal of Pharmaceutical Research</full_title>
        <abbrev_title>Univ J Pharm Res</abbrev_title>
        <issn media_type="electronic">2456-8058</issn>
        <issn media_type="print">2831-5235</issn>
      </journal_metadata>
      <journal_issue>
        <publication_date media_type="online">
          <month>01</month>
          <day>15</day>
          <year>2024</year>
        </publication_date>
      </journal_issue>
      <journal_article xmlns:jats="http://www.ncbi.nlm.nih.gov/JATS1" xmlns:ai="http://www.crossref.org/AccessIndicators.xsd" publication_type="full_text" metadata_distribution_opts="any">
        <titles>
          <title>OUTCOME OF AZITHROMYCIN AND MONOSODIUM GLUTAMATE ON HISTOLOGIC AND BIOCHEMICAL ALTERATIONS IN RATS’ LIVER</title>
        </titles>
        <contributors>
          <person_name contributor_role="author" sequence="first" language="en">
            <given_name>Anthony Cemaluk Chinedum</given_name>
            <surname>Egbuonu</surname>
            <ORCID>https://orcid.org/0000-0001-5974-415X</ORCID>
          </person_name>
          <person_name contributor_role="author" sequence="additional" language="en">
            <given_name>Prince Ogochukwu</given_name>
            <surname>Alaebo</surname>
            <ORCID>https://orcid.org/0000-0003-3579-6822</ORCID>
          </person_name>
          <person_name contributor_role="author" sequence="additional" language="en">
            <given_name>Obioma Benedeth</given_name>
            <surname>Eze</surname>
            <ORCID>https://orcid.org/0000-0003-2113-2312</ORCID>
          </person_name>
          <person_name contributor_role="author" sequence="additional" language="en">
            <given_name>Ngozi Kalu</given_name>
            <surname>Achi</surname>
            <ORCID>https://orcid.org/0009-0002-8780-9947</ORCID>
          </person_name>
          <person_name contributor_role="author" sequence="additional" language="en">
            <given_name>Chinomso Juliet</given_name>
            <surname>Njoku</surname>
            <ORCID>https://orcid.org/0009-0002-8780-9947</ORCID>
          </person_name>
        </contributors>
        <jats:abstract xmlns:jats="http://www.ncbi.nlm.nih.gov/JATS1">
          <jats:p>Background: Monosodium glutamate (MSG), a commonly used flavouring, mediated hepatotoxic and pro-inflammatory responses. Azithromycin (AZT), an antibiotic with anti-inflammatory activity, may be co-consumed with MSG to present unknown outcomes on the liver, a major organ for the detoxification of xenobiotics.
Aim: This study evaluated the effect of AZT and MSG on histologic and biochemical changes in rats’ liver.
Methods: Thirty rats in five groups were for seven successive days orally exposed to groups 1, (distilled water 1 mL Kg−1), 2, (MSG 8000 mg/kg), 3, overdose AZT, OAZT (AZT 412.5 mg Kg−1), 4, therapeutic concentration AZT, TAZT, (AZT 82.5mg Kg−1), and 5, (TAZT 82.5 mg Kg−1 + MSG 8000 mg Kg−1). Liver function markers in therats’ serum and liver tissue, and changes in the liver histologic were assessed by acceptable protocols. The mean of numeric data were tested for significance at p value less than 0.05 by analysis of variance (ANOVA).
Results: MSG treatment significantly (p&lt;0.05) increased hepatic and serum alanine aminotransferase activity (ALT), aspartate aminotransferase activity (AST), alkaline phosphatase activity (ALP), total bilirubin concentration (T-BIL), and direct bilirubin concentration (D-BIL) but decreased albumin concentration (ALB) compared to control and others. TAZT treatment caused a significant (p&lt;0.05) decrease in these effects unlike MSG and OATZ treatments while TAZT + MSG co-treatment significantly (p&lt;0.05) reversed these effects compared to MSG-treated rats. Rats’ liver sections for rats in groups 2 and 3 showed severe hepatocellular degeneration and necrosis compared to others while those in group 4 (TAZT) showed the normal hepatic histo-architecture comparable to those in group 1 (control). Those in group 5 showed marked cellular swelling and leukocytic infiltration in only the centrilobular areas, suggesting active restorative responses.
Conclusion: Thus, TAZT significantly mitigated the compromised histologic and biochemical integrities of liver function due to MSG treatment in rats via probable normalization of their enzymatic and non-enzymatic indicators of liver function. This suggests that TAZT could be useful in managing histologic and biochemical malfunction of rats’ liver due to MSG assault.
                   
Peer Review History: 
Received: 12 October 2023; Revised: 9 November; Accepted: 13 December, Available online: 15 January 2024
Academic Editor: Dr. Marwa A. A. Fayed, University of Sadat City, Egypt, maafayed@gmail.com
Received file:                             Reviewer's Comments:
Average Peer review marks at initial stage: 6.0/10
Average Peer review marks at publication stage: 7.0/10
Reviewers:
Idoko Alexander, Caritas University, Enugu, Nigeria, idokoalexander1@gmail.com
Dr. Dennis Amaechi, MrsFoluBabade Mini Estate, Flat 5 by Old Soldiers Quarter, Sabongari/Bwari, Abuja- Federal Capital Territory, Nigeria. amaechitoexcel@yahoo.com </jats:p>
        </jats:abstract>
        <publication_date media_type="online">
          <month>01</month>
          <day>15</day>
          <year>2024</year>
        </publication_date>
        <fr:program name="fundref"/>
        <ai:program xmlns:ai="http://www.crossref.org/AccessIndicators.xsd" name="AccessIndicators">
          <ai:license_ref>http://creativecommons.org/licenses/by-nc/4.0</ai:license_ref>
        </ai:program>
        <doi_data>
          <doi>10.22270/ujpr.v8i6.1040</doi>
          <resource>https://www.ujpr.org/index.php/journal/article/view/1040</resource>
          <collection property="crawler-based">
            <item crawler="iParadigms">
              <resource>https://www.ujpr.org/index.php/journal/article/download/1040/1519</resource>
            </item>
          </collection>
          <collection property="text-mining">
            <item>
              <resource mime_type="application/pdf">https://www.ujpr.org/index.php/journal/article/download/1040/1519</resource>
            </item>
            <item>
              <resource mime_type="text/xml">https://www.ujpr.org/index.php/journal/article/download/1040/1532</resource>
            </item>
            <item>
              <resource mime_type="text/html">https://www.ujpr.org/index.php/journal/article/download/1040/1547</resource>
            </item>
          </collection>
        </doi_data>
      </journal_article>
    </journal>
  </body>
</doi_batch>
